文献速递免疫规划

重组四价流感疫苗与灭活流感疫苗在中国成人中的安全性比较:一项观察性研究

Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study.
PubMed 文献 · Vaccine · 2022-01-06

在美国北加州凯撒医疗集团2018-2019流感季,自我认同为华人的18-64岁成人中,比较接种重组四价流感疫苗(RIV4)与标准剂量四价灭活流感疫苗(SD-IIV4)后的安全性。研究比较接种后0-2天、0-13天和0-41天急诊和住院预设诊断率及0-180天死亡数,采用logistic回归估计比值比(OR)及95%置信区间。结果显示两组预设诊断和死亡无统计学显著差异,共35例死亡,均未认为与流感疫苗接种相关。

要点

  • 在自我认同为华人的18-64岁成人中,RIV4组与SD-IIV4组的预设诊断和死亡无统计学显著差异。
  • 共报告35例死亡,均未认为与流感疫苗接种相关。
  • 本研究未发现RIV4在该人群中使用的安全性问题,支持RIV4疫苗在该人群中的安全性。

核心结论

  • 本研究未发现RIV4在自我认同为华人的18-64岁成人中使用存在安全性问题。
  • 本研究支持RIV4疫苗在该人群中的安全性。

研究设计与样本

  • 观察性研究,纳入美国北加州凯撒医疗集团2018-2019流感季自我认同为华人的18-64岁成人(NCT03694392)。
  • 比较接种RIV4的15,574名成人与接种SD-IIV4的27,110名成人。
  • 比较接种后0-2天、0-13天和0-41天急诊和住院预设诊断率及0-180天死亡数。
  • 采用logistic回归估计比值比(OR)及95%置信区间,调整性别、年龄组、合并症及同日伴随接种。

主要发现

  • RIV4组15,574人与SD-IIV4组27,110人相比,预设诊断和死亡无统计学显著差异。
  • 共报告35例死亡,均未认为与流感疫苗接种相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recombinant influenza vaccine (RIV) has been in use in US adults since 2013. This study evaluated the safety of quadrivalent recombinant influenza vaccine (RIV4, Flublok® Quadrivalent, Sanofi Pasteur) compared with standard-dose quadrivalent inactivated influenza vaccine (SD-IIV4) in self-identified Chinese adults at Kaiser Permanente Northern California (KPNC). METHODS: This study evaluated adults aged 18-64 years within KPNC during the 2018-2019 influenza season who self-identified as Chinese (NCT03694392). We compared the rates of prespecified diagnoses of interest in the emergency department and inpatient settings as done in prior influenza studies, for three risk intervals: 0-2 days, 0-13 days, and 0-41 days following influenza vaccination, as well as number of deaths within 0-180 days after vaccination. We estimated the odds ratios (ORs) and 95% confidence intervals using logistic regression adjusted for sex, age group, presence of comorbidities, and same-day concomitant vaccination. RESULTS: Comparing 15,574 adults who received RIV4 with 27,110 who received SD-IIV4, there was no statistically significant difference in the prespecified diagnoses of interest and deaths between the 2 groups. There were 35 deaths total, none of which were considered to be related to influenza vaccination. CONCLUSIONS: This study did not identify any safety concerns regarding RIV4 use among 18-64-year-olds who self-identified as Chinese. This study supports the safety of RIV4 vaccine in this population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hsiao A, Hansen J, Nunley KV, et al. Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study. Vaccine. 2022. PMID: 34998605. doi:10.1016/j.vaccine.2021.12.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。